prostate cancer

New urine test has higher diagnostic accuracy for prostate cancer

Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the U.S.

Long-term follow-up pinpoints side effects of treatments for prostate cancer patients

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population.

Polygenic “scores” may improve cancer screening

Accounting for genetic variability in biomarkers not associated with cancer risk could avoid unnecessary diagnostic procedures, Vanderbilt researchers found.

Prostate cancer survivors symposium set for Nov. 11

Vanderbilt University Medical Center Department of Urology and Vanderbilt-Ingram Cancer Center are hosting a symposium for prostate cancer survivors and their families on Saturday, Nov. 11.

International workgroup of geneticists issues CHEK2 guidelines

International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.

More U.S. prostate cancer patients choosing active surveillance

A Vanderbilt study found the number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable intermediate-risk cancers.